Judge Approves $3M Securities Settlement For Misleading COVID-19 Treatment Claims
NEWARK, N.J. — A New Jersey federal judge granted final approval of a $3 million settlement including $750,000 in attorney fees to resolve a securities class action against a pharmaceutical company...To view the full article, register now.
Already a subscriber? Click here to view full article